Soluble guanylate cyclase stimulators

US10428076B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Raphaelle Berger · New York, US
• Yi-Heng Chen · Whippany, US
• Guoqing Li · Montgomery, US
• Joie Garfunkle · Metuchen, US
• Hong Li · Edison, US
• Shouwu Miao · Edison, US
• Subharekha Raghavan · Teaneck, US
• Cameron Smith · Lawrenceville, US
• John E. Stelmach · Westfield, US
• Alan Whitehead · Scotch Plains, US
• Rui Zhang · Plainsboro, US
• Yong Zhang · Plainsboro, US
• Jianmin Fu · Beijing, CN
• Gang Ji · Beijing, CN
• Falong Jiang · Beijing, CN

Key dates

• Filing date: Jun 27, 2018
• Grant date: Oct 1, 2019
• Expiry date: Jun 27, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.